INT75685

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 1998
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 12
Total Number 13
Disease Relevance 3.55
Pain Relevance 2.66

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (CD86) cell-cell signaling (CD86)
Anatomy Link Frequency
CD86 6
T-cell 3
monocyte 2
macrophages 1
plasma 1
CD86 (Homo sapiens)
Pain Link Frequency Relevance Heat
abatacept 184 99.74 Very High Very High Very High
rheumatoid arthritis 33 99.64 Very High Very High Very High
cytokine 191 98.96 Very High Very High Very High
Infliximab 93 95.32 Very High Very High Very High
methotrexate 27 93.84 High High
local anesthetic 1 82.32 Quite High
Inflammatory mediators 16 78.32 Quite High
chemokine 78 73.56 Quite High
agonist 24 69.60 Quite High
corticosteroid 19 64.72 Quite High
Disease Link Frequency Relevance Heat
Rheumatoid Arthritis 33 99.64 Very High Very High Very High
Disease 85 93.68 High High
Infection 174 92.24 High High
Urological Neuroanatomy 22 89.36 High High
Viral Meningitis 4 85.84 High High
Cold Sores 367 85.24 High High
INFLAMMATION 275 78.32 Quite High
Peritonitis 30 73.76 Quite High
Hookworm Infection 37 72.56 Quite High
Asthma 328 69.84 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Abatacept is the first in a class of agents for the treatment of RA that selectively modulates the CD80/CD86:CD28 co-stimulatory signal required for full T-cell activation [4].
Regulation (modulates) of CD86 in T-cell associated with rheumatoid arthritis and abatacept
1) Confidence 0.58 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1906816 Disease Relevance 0.26 Pain Relevance 0.62
CD86 modulation calculated as the difference between the results obtained for the treated sample and the corresponding untreated control (?
Regulation (modulation) of CD86 in CD86
2) Confidence 0.45 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3009729 Disease Relevance 0.06 Pain Relevance 0.06
The modulation of the cell surface molecules CD86, CD83 and HLA-DR was measured after DC exposure to known photoallergenic and phototoxic as well as allergenic and non-allergenic chemicals or to irradiation only.
Regulation (modulation) of CD86 in CD86
3) Confidence 0.27 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3009729 Disease Relevance 0.07 Pain Relevance 0.04
Abatacept is a selective T-cell co-stimulation modulator, that modulates the CD80/CD86:CD28 co-stimulatory signal required for full T-cell activation.1 The mechanism of action of abatacept is fundamentally different to that of other biological disease-modifying antirheumatic drugs (DMARDs) for the treatment of rheumatoid arthritis (RA).
Regulation (modulates) of CD86 in T-cell associated with rheumatoid arthritis, abatacept and disease
4) Confidence 0.26 Published 2008 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2564802 Disease Relevance 0.63 Pain Relevance 0.64
Abatacept selectively modulates the CD80/CD86:CD28 co-stimulatory signal required for full T-cell activation, and has been approved for the treatment of rheumatoid arthritis (RA) in combination with methotrexate in a number of countries, including the United States, Canada, and the European Union.
Regulation (modulates) of CD86 in T-cell associated with rheumatoid arthritis, abatacept and methotrexate
5) Confidence 0.26 Published 2007 Journal Clin. Exp. Rheumatol. Section Abstract Doc Link 17977488 Disease Relevance 0.38 Pain Relevance 0.52
While this is indeed the case for matured DCs from non-infected donors, mDCs from Necator-infected individuals have a down-regulated expression of antigen-presenting, costimulatory (CD86) molecules, and CD11c, with the CD14 still present on the cell surface.
Regulation (regulated) of CD86 in CD86
6) Confidence 0.23 Published 2009 Journal PLoS Neglected Tropical Diseases Section Body Doc Link PMC2654967 Disease Relevance 0.40 Pain Relevance 0.12
Figure 3 shows the effect of 0.5 and 2 mg pretreatments with FP on O3-induced changes in the cell-surface markers CD11b, mCD14, CD64, CD16, HLA-DR, and CD86 on monocytes, macrophages, and DCs.
Regulation (effect) of CD86 in macrophages
7) Confidence 0.23 Published 2008 Journal Environ Health Perspect Section Body Doc Link PMC2430237 Disease Relevance 0.25 Pain Relevance 0
The effect of three iodinated contrast media (CM) on human plasma butyrylcholinesterase (BuChE) activity was studied during the intravenous pyelography (i.v.P).
Regulation (effect) of BuChE in plasma
8) Confidence 0.18 Published 1998 Journal Invest Radiol Section Abstract Doc Link 9609490 Disease Relevance 0 Pain Relevance 0.08
The Th2 skewing of the developing immune response is explained by the effects of PDE inhibitors on several factors contributing to T cell priming: the cytokine milieu; the type of costimulatory signal, i.e., up-regulation of CD86 and down-regulation of CD80; and the antigen avidity [57].
Regulation (regulation) of CD86 in CD86 associated with cytokine
9) Confidence 0.18 Published 2008 Journal J Occup Med Toxicol Section Body Doc Link PMC2259400 Disease Relevance 0.13 Pain Relevance 0.35
Recently, it has been shown that the complex of the four glycoproteins gB, gD, gH and gL, which are essential for viral attachment/entry (Fig. 3), expressed on the surface of Cos7 cells mediates monocyte-derived DC recognition via a nucleic acid-independent and TLR-independent pathway, leading to the up-regulation of CD40, CD83, CD86 and HLA-DR and to the production of IFN-?
Regulation (regulation) of CD86 in monocyte
10) Confidence 0.08 Published 2010 Journal The Open Virology Journal Section Body Doc Link PMC2936037 Disease Relevance 0.77 Pain Relevance 0.10
Figure 3 shows the effect of 0.5 and 2 mg pretreatments with FP on O3-induced changes in the cell-surface markers CD11b, mCD14, CD64, CD16, HLA-DR, and CD86 on monocytes, macrophages, and DCs.
Regulation (effect) of CD86 in monocytes
11) Confidence 0.08 Published 2008 Journal Environ Health Perspect Section Body Doc Link PMC2430237 Disease Relevance 0.25 Pain Relevance 0
In the same cultures, monocytes showed a corresponding dose-dependent response to HMB-PP at 0.1 nM and higher, as judged by increased forward scatter, down-modulation of CD14, up-regulation of CD40 and CD86, and induction of TRAIL and TNF-?
Regulation (regulation) of CD86 in CD86
12) Confidence 0.08 Published 2009 Journal PLoS Pathogens Section Body Doc Link PMC2637987 Disease Relevance 0.34 Pain Relevance 0.09
also appeared to be the major regulators of cell surface CD14, CD40, and CD86 expression, whereas GM-CSF and IL-4 had only minor effects (Fig. 4B).
Regulation (regulators) of CD86 in CD86
13) Confidence 0.03 Published 2009 Journal PLoS Pathogens Section Body Doc Link PMC2637987 Disease Relevance 0 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox